neoadjuvant immunotherapy

5 · 20 / page

Ask MedXY AI

Latest news

Tag

newsesophageal squamous cell carcinomaIL-6

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker

By MedXY|Dec 9, 2025

The multicenter PALACE-2 trial reports a 43.2% pathological complete response (pCR) with preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma and identifies baseline serum IL-6 as a po

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

newsesophageal squamous cell carcinomaneoadjuvant immunotherapy

neoadjuvant immunotherapy

Latest news

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

Pathologic Response to Neoadjuvant Nivolumab Predicts Improved Survival in HPV‑Negative Head and Neck Cancer

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma